The P2Y11 receptor of human M2 macrophages activates canonical and IL-1 receptor signaling to translate the extracellular danger signal ATP into anti-inflammatory and pro-angiogenic responses

Cell Mol Life Sci. 2022 Sep 15;79(10):519. doi: 10.1007/s00018-022-04548-z.

Abstract

The cytoprotective ATP receptor P2Y11 is upregulated during M2 macrophage differentiation and contributes to the anti-inflammatory properties of this macrophage subset. Here, we studied P2Y11-induced reprogramming of human M2 macrophages at the level of mRNA and protein expression. Upregulation of IL-1 receptor (IL-1R) and its known downstream effectors VEGF, CCL20 and SOCS3 as well as downregulation of the ATP-degrading ecto-ATPase CD39 emerged as hallmarks of P2Y11 activation. The anti-inflammatory signature of the P2Y11 transcriptome was further characterized by the downregulation of P2RX7, toll-like receptors and inflammasome components. P2Y11-induced IL-1R upregulation formed the basis for reinforced IL-1 responsiveness of activated M2 macrophages, as IL-1α and IL-1ß each enhanced P2Y11-induced secretion of VEGF and CCL20 as well as the previously reported shedding of soluble tumor necrosis factor receptor 2 (sTNFR2). Raising intracellular cyclic AMP (cAMP) in M2 macrophages through phosphodiesterase 4 inhibition enhanced P2Y11-driven responses. The cAMP-binding effector, exchange protein activated by cAMP 1 (Epac1), which is known to induce SOCS3, differentially regulated the P2Y11/IL-1R response because pharmacological Epac1 inhibition enhanced sTNFR2 and CCL20 release, but had no effect on VEGF secretion. In addition to cAMP, calcium and protein kinase C participated in P2Y11 signaling. Our study reveals how P2Y11 harnesses canonical and IL-1R signaling to promote an anti-inflammatory and pro-angiogenic switch of human M2 macrophages, which may be controlled in part by an Epac1-SOCS3 axis.

Keywords: Homeostasis; Macrophage polarization; NanoString; Purinergic signaling.

MeSH terms

  • Adenosine Triphosphate / metabolism
  • Anti-Inflammatory Agents / metabolism
  • Calcium / metabolism
  • Cyclic AMP / metabolism
  • Cyclic Nucleotide Phosphodiesterases, Type 4 / metabolism
  • Humans
  • Inflammasomes / metabolism
  • Interleukin-1 / metabolism
  • Macrophages / metabolism
  • Protein Kinase C / metabolism
  • RNA, Messenger / genetics
  • Receptors, Interleukin-1*
  • Receptors, Purinergic P2 / genetics
  • Receptors, Purinergic P2 / metabolism*
  • Receptors, Tumor Necrosis Factor, Type II / metabolism
  • Suppressor of Cytokine Signaling Proteins / metabolism
  • Vascular Endothelial Growth Factor A / metabolism

Substances

  • Anti-Inflammatory Agents
  • Inflammasomes
  • Interleukin-1
  • P2RY11 protein, human
  • RNA, Messenger
  • Receptors, Interleukin-1
  • Receptors, Purinergic P2
  • Receptors, Tumor Necrosis Factor, Type II
  • Suppressor of Cytokine Signaling Proteins
  • Vascular Endothelial Growth Factor A
  • Adenosine Triphosphate
  • Cyclic AMP
  • Protein Kinase C
  • Cyclic Nucleotide Phosphodiesterases, Type 4
  • Calcium